Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | DHCR24 | Q15392 | 11/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | RORC | P51449 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24300840 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL188329 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL335520 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL335521 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL30650209 | 0.93 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL9155413 | 0.90 | RORC (0.80) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL7624350 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL15123702 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL14911153 | 0.87 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL1237838 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2AUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049617-B2 | Optimization of C-8 sterol isomerization | DSM IP ASSETS B.V. (NL) | 2024-07-30 | — | — | US | claimed |
| US-20210238539-A1 | OPTIMIZATION OF C-8 STEROL ISOMERIZATION | DSM IP ASSETS B.V. (NL) | 2021-08-05 | — | — | US | claimed |
| US-20210222222-A1 | OPTIMIZATION OF C-5 STEROL DESATURATION | DSM IP ASSETS B.V. (NL) | 2021-07-22 | — | — | US | claimed |
| EP-3797168-A1 | OPTIMIZATION OF C-5 STEROL DESATURATION | DSM IP Assets B.V. (NL) | 2021-03-31 | — | — | EP | claimed |
| EP-3797161-A1 | OPTIMIZATION OF C-8 STEROL ISOMERIZATION | DSM IP Assets B.V. (NL) | 2021-03-31 | — | — | EP | claimed |
| CN-112154213-A | Optimization of C-5 sterol desaturation | 帝斯曼知识产权资产管理有限公司 | 2020-12-29 | — | — | CN | claimed |
| CN-112135905-A | Optimization of C-8 sterol isomerization | 帝斯曼知识产权资产管理有限公司 | 2020-12-25 | — | — | CN | claimed |
| US-9624521-B2 | Production of non-yeast sterols by yeast | DSM IP ASSETS B.V. (NL) | 2017-04-18 | — | — | US | claimed |
| EP-2507368-B1 | PRODUCTION OF NON-YEAST STEROLS BY YEAST | DSM IP ASSETS BV (NL) | 2016-03-30 | — | — | EP | claimed |
| EP-2507368-A1 | PRODUCTION OF NON-YEAST STEROLS BY YEAST | DSM IP Assets B.V. (NL) | 2012-10-10 | — | — | EP | claimed |
| US-20120231495-A1 | PRODUCTION OF NON-YEAST STEROLS BY YEAST | DSM IP ASSETS, B.V. (NL) | 2012-09-13 | — | — | US | claimed |
| WO-2011067144-A1 | PRODUCTION OF NON-YEAST STEROLS BY YEAST | DSM IP ASSETS B.V. (NL) | 2011-06-09 | — | — | WO | claimed |
| EP-0486290-B1 | A method and composition for increasing the accumulation of squalene and specific sterols in yeast | BP CORP NORTH AMERICA INC (US) | 2002-05-22 | — | — | EP | claimed |
| US-5460949-A | Increasing gene expression encoding polypeptide having HMG-CoA activity in mutant yeast; culturing | AMOCO CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
| US-5391777-A | Isolation of steroids containing a 5,7-diene functionality from a sterol mixture | SRI INTERNATIONAL (US) | 1995-02-21 | — | — | US | claimed |
| EP-0486290-A2 | A method and composition for increasing the accumulation of squalene and specific sterols in yeast | AMOCO CORPORATION (US) | 1992-05-20 | — | — | EP | claimed |
| US-12630852-B2 | Modified sterol acyltransferases | DSM IP ASSETS B.V. (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260009064-A1 | STEROL PRODUCTION IN YEAST | Apix Biosciences (BE) | 2026-01-08 | — | — | US | disclosed |
| WO-1992000076-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A COMBINATION OF A RETINOID AND A STEROL | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-01-09 | — | — | WO | disclosed |
| EP-0465343-A1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630852-B2 | Modified sterol acyltransferases | CYP46A1, DHCR7, CYP2R1 | ALDH1A1 887/4885MEN1 2661/4885KMT2A 1479/4885 |
| US-20260009064-A1 | STEROL PRODUCTION IN YEAST | SREBF2, ERG28, SREBF1 | ALDH1A1 2749/4885MEN1 2504/4885KMT2A 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.